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and Acronyms
BMS = bare-metal stent(s)
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GPI = glycoprotein IIb/IIIa
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NSTEACS = non–ST-segment
elevation acute coronary
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intervention
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1846Compared with bare-metal stents
(BMS), drug-eluting stents (DES)
improve clinical and angiographic
outcomes in patients with coro-
nary artery disease undergoing
percutaneous coronary interven-
tion (PCI) (1,2). Although favo-
rable results may be achieved with
PCI in complex lesions (3–6),
patients with moderately and
severely calciﬁed lesions have
been excluded from enrollment in
most stent trials and still repre-
sent a challenge even in the DES
era. Coronary calciﬁcation may
impair stent delivery and expan-
sion and damage the polymer/
drug coating, resulting in im-
paired drug delivery and predis-position to restenosis and stent thrombosis (7). Whereas
small studies in the BMS era demonstrated reduced event-
free survival after PCI of calciﬁed compared with non-
calciﬁed lesions, surprisingly little is known about the effect
of coronary calciﬁcation on outcomes after PCI with DESpage 1855(8–12). Moreover, no studies have evaluated the frequency
and impact of coronary calciﬁcation in patients presenting
with non–ST-segment elevation acute coronary syndromes
(NSTEACS) and ST-segment elevation myocardial infarc-
tion (STEMI). We therefore sought to determine the fre-
quency and impact of target lesion coronary calciﬁcation on
clinical events in patients in whom PCI was performed in
the setting of NSTEACS or STEMI in a pooled analysis
from the large-scale ACUITY (Acute Catheterization and
Urgent Intervention Triage Strategy) andHORIZONS-AMI
(Harmonizing Outcomes With Revascularization and Stents
in Acute Myocardial Infarction) trials (13,14).
Methods
Study designs and patients. The ACUITY and
HORIZONS-AMI trial designs and results have previously
been described in detail (13–16). In brief, ACUITY was a
multicenter, prospective, randomized trial of 13,819 patients
with moderate- and high-risk NSTEACS who were treated
with an early invasive strategy. Prior to coronary angiog-
raphy, patients were randomly assigned to heparin (unfrac-
tionated or low-molecular-weight) plus a glycoprotein IIb/er in Endothelix. Dr. Stone has served as a
Cardiovascular Systems, Inc. All other authors
ionships relevant to the contents of this paper
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; revised manuscript received January 5, 2014,IIIa inhibitor (GPI), bivalirudin plus a GPI, or bivalirudin
monotherapy. Angiography was performed within 72 h of
randomization, and depending on coronary anatomy, patients
were triaged to PCI, coronary artery bypass graft (CABG)
surgery, or medical therapy. In patients undergoing PCI,
stent choice (BMS or DES) was per operator discretion. Dual
antiplatelet therapy with aspirin and clopidogrel was recom-
mended for at least 1 year. In HORIZONS-AMI, 3,602
patients with STEMI presenting within 12 h of symptom
onset were randomly assigned to unfractionated heparin plus
GPI or bivalirudin monotherapy. Immediate coronary angi-
ographywas performed after randomization, followed byPCI,
CABG, or medical management at physician discretion.
Eligible patients were randomized again (3:1) to receive
paclitaxel-eluting stents (Boston Scientiﬁc, Natick, Massa-
chusetts) or otherwise identical BMS (Boston Scientiﬁc).
Aspirin and clopidogrel were administered before catheteri-
zation; aspirin was continued indeﬁnitely and clopidogrel for
at least 1 year (14,16). Patients with severe renal insufﬁciency
(calculated creatinine clearance <30 ml/min) were not
included in either trial.
Patients in whom qualitative and quantitative coronary
angiography (QCA) was performed comprised the present
study population. QCA was performed at the Cardiovas-
cular Research Foundation (New York, New York) by
technicians blinded to randomization and outcomes in all
patients in the HORIZONS-AMI trial and in those en-
rolled in the formal ACUITY angiographic substudy, as
previously described (17). Interobserver and intraobserver
QCA core laboratory variability kappa values (50 coronary
angiograms assessed twice [8 weeks apart] by 12 angio-
graphic core laboratory technicians) for the degree of target
lesion calciﬁcation were 0.83 and 0.89, respectively, repre-
senting excellent agreement. Independent clinical events
committees, blinded to treatment assignment, adjudicated
all major adverse events in both trials.
Objectives and angiographic analysis. The primary study
objective was to assess the relationship between the presence
and extent of target lesion coronary calciﬁcation and the
1-year rate of ischemic events, including death, cardiac
death, reinfarction, deﬁnite stent thrombosis, and ischemic
target lesion revascularization (TLR) and target vessel
revascularization. For the present report, we limited our
analyses to the patients with STEMI in whom PCI was
performed in the HORIZONS-AMI trial and to the
patients with NSTEACS in whom PCI was performed in
the formal angiographic substudy from ACUITY (17).
Endpoint deﬁnitions and statistical analysis. The ACUITY
and HORIZONS databases were combined, and patients
from this pooled population were stratiﬁed on the basis of
severity of coronary artery calciﬁcation (none/mild, moder-
ate, and severe). The pre-speciﬁed angiographic core labo-
ratory deﬁnition of moderate calciﬁcation was radiopaque
densities noted only during the cardiac cycle and typically
involving only one side of the vascular wall. Severe calciﬁ-
cation was deﬁned as radiopaque densities noted without
Table 1
Baseline Clinical Characteristics of Patients Stratiﬁed by the Severity of
Target Lesion Calciﬁcation
No/Mild
Calciﬁcation
(N ¼ 4,665)
Moderate
Calciﬁcation
(N ¼ 1,788)
Severe
Calciﬁcation
(N ¼ 402) p Value
Age, yrs 59.2 (51.7–69.0) 63.1 (55.0–72.0) 65.3 (55.8–74.0) <0.0001
Male 3,385/4,665 (72.6) 1,342/1,788 (75.1) 292/402 (72.6) 0.12
Diabetes 1,143/4,651 (24.6) 418/1,784 (23.4) 103/402 (25.6) 0.52
Insulin treated 324/4,651 (7.0) 114/1,784 (6.4) 35/402 (8.7) 0.25
Hypertension 2,849/4,652 (61.2) 1,112/1,784 (62.3) 249/402 (61.9) 0.71
Hyperlipidemia 2,452/4,630 (53.0) 934/1,780 (52.5) 201/399 (50.4) 0.60
Current smoker 1,842/4,658 (39.5) 667/1,779 (37.5) 141/401 (35.2) 0.10
Previous myocardial infarction 1,076/4,598 (23.4) 406/1,765 (23.0) 72/398 (18.1) 0.05
Previous PCI 1,440/4,652 (31.0) 493/1,782 (27.7) 93/401 (23.2) 0.0005
Previous CABG 579/4,658 (12.4) 243/1,786 (13.6) 58/402 (14.4) 0.28
Previous stroke 165/2,609 (6.3) 54/804 (6.7) 11/144 (7.6) 0.78
Renal insufﬁciency 642/4,362 (14.7) 326/1,657 (19.7) 107/374 (28.6) <0.0001
Left ventricular ejection fraction 62.6 (53.8–70.8) 61.3 (52.1–69.0) 59.6 (51.7–67.8) <0.0001
Baseline laboratory values
WBC count,  103/l 9.1 (7.1–11.6) 9.4 (7.4–11.8) 10.0 (7.8–12.2) <0.0001
Hemoglobin, g/dl 14.3 (13.2–15.3) 14.2 (13.2–15.3) 14.1 (13.1–15.3) 0.33
Platelet count, 103/mm3 236.0 (197.0–282.0) 237.0 (199.0–279.0) 238.0 (195.0–286.0) 0.84
Clinical presentation
STEMI 2,036/4,665 (43.6) 976/1,788 (54.6) 256/402 (63.7) <0.0001
NSTEMI 1,396/4,665 (29.9) 444/1,788 (24.8) 86/402 (21.4) <0.0001
Unstable angina 1,233/4,665 (26.4) 368/1,788 (20.8) 60/402 (14.9) <0.0001
Values are median (interquartile range) or n/N (%). Hypertension is deﬁned as previous diagnosis of hypertension and on antihypertensive medication on
admission. Hyperlipidemia is deﬁned as previous diagnosis of hyperlipidemia and on lipid-lowering medication on admission. Renal insufﬁciency is deﬁned
as a calculated creatinine clearance rate <60 ml/min by the Cockcroft-Gault equation.
CABG ¼ coronary artery bypass graft; NSTEMI ¼ non–ST-segment elevation myocardial infarction; PCI = percutaneous coronary intervention; STEMI = ST-
segment elevation myocardial infarction; WBC = white blood cells.
Table 2
Independent Predictors of the Presence of
Moderate/Severe Target Lesion Calciﬁcation
Hazard Ratio (95% CI) p Value
Age (per 10-yr increase) 1.29 (1.23–1.35) <0.0001
Male 1.29 (1.12–1.50) <0.0001
STEMI 1.55 (1.37–1.76) <0.0001
Hypertension 1.12 (1.02–1.31) 0.02
Other covariates included in the model were current smoker, diabetes (any), previous myocardial
infarction, previous CABG surgery, renal insufﬁciency, hyperlipidemia, baseline WBC count, and left
ventricular ejection fraction.
CI ¼ conﬁdence interval; other abbreviations as in Table 1.
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1847cardiac motion prior to contrast injection and generally
involving both sides of the arterial wall (18). Major adverse
cardiovascular events (MACE) were deﬁned as the com-
posite of death, reinfarction, and unplanned revasculariza-
tion for ischemia. The speciﬁc deﬁnitions of the components
of MACE have been previously described (13,14).
Categorical data were compared by the chi-square test or
Fisher exact test if the expected number of observations in
any cell was <5. Continuous data are presented as mean
 SD or median  interquartile range and were compared
using the analysis of variance or Kruskal-Wallis test as
appropriate. The 30-day event rates were estimated using
Kaplan-Meier time-to-event methodology and were com-
pared using the log-rank test. Multivariable regression
analysis using Cox proportional hazards models to assess for
independent predictors for the presence of target lesion
coronary artery calciﬁcation and for the association between
the presence of coronary calciﬁcation and 1-year ischemic
outcomes were performed with variable entry/stay criteria of
0.1/0.1. Variables included into the model were carefully
selected to avoid overﬁtting of the model. Because of the
relatively small number of patients with severe coronary
calciﬁcation, the moderate and severe target lesion calciﬁca-
tion groups were pooled for these analyses. Values of
p< 0.05 were considered to be statistically signiﬁcant, and all
p values are 2-sided. Statistical analyses were performed us-
ing SAS version 9.2 (SAS Institute, Cary, North Carolina).Results
From the angiographic substudy of ACUITY (NSTEACS)
and HORIZONS-AMI (STEMI), 3,587 and 3,268 pa-
tients, respectively, undergoing PCI were pooled, for a total of
6,855 patients comprising the study population. A total of
8,381 target lesions were present, of which 451 (5.4%), 2,138
(25.5%), and 5,792 (69.1%) were assessed by the angiographic
core laboratory as heavily calciﬁed, moderately calciﬁed, and
none/mildly calciﬁed, respectively. Target lesion calciﬁcation
was severe in 402 patients (5.9%) in whom PCI was per-
formed in 550 total lesions; moderate in 1,788 patients
(26.1%) in whom PCI was performed in 2,430 total lesions;
and none/mild in 4,665 patients (68.1%) in whom PCI was
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1848performed in 5,829 total lesions. A total of 54 patients had
both moderately and severely calciﬁed lesions.
Patient characteristics, angiographic ﬁndings, and treatment
randomization. As shown in Table 1 and Online Table 1,
compared with patients without calciﬁed lesions, patients withTable 3
Angiographic Characteristics and Procedu
of Target Lesion Calciﬁcation
No/Mild
Calciﬁcation
(N ¼ 4,665)
Antithrombotic medication
Bivalirudin monotherapy 1,914/4,665 (41.0)
Bivalirudin þ GPI 901/4,665 (19.3)
Heparin þ GPI 1,850/4,665 (39.7)
Number of lesions treated 1.31  0.67
Number of stents implanted 1.31  0.74
Drug-eluting stent 3,660/4,609 (79.4)
Lesion level
Baseline QCA
Lesion length, mm 13.0 (10.0–19.0)
RVD, mm 2.79 (2.41–3.15)
MLD, mm 0.53 (0.07–0.89)
Diameter stenosis, % 80.2 (66.3–97.9)
Total occlusion 1,444/5,824 (24.8)
Tortuosity (moderate/severe) 107/5,811 (1.8)
Thrombus 2,144/5,813 (36.9)
Bifurcation present 2,218/5,829 (38.1)
Target vessel
Right coronary artery 2,143/5,818 (36.8)
Left circumﬂex 1,499/5,818 (25.8)
Left anterior descending 2,155/5,818 (37.0)
2-vessel disease 1,562/4,658 (33.2)
3-vessel disease 1,541/4,658 (33.1)
Extent of disease, mm 33.5 (19.8–53.0)
Final QCA
MLD, mm
In-stent 2.70 (2.37–3.03)
In-segment 2.32 (1.97–2.70)
Residual degree stenosis, %
In-stent 6.7 (3.6–10.5)
In-segment 16.5 (10.7–23.2)
Acute gain, mm
In-stent 2.13 (1.67–2.57)
Vessel level
TIMI ﬂow grade
Baseline TIMI 0/1 1,713/5,810 (29.5)
Baseline TIMI 2 641/5,810 (11.0)
Baseline TIMI 3 3,456/5,810 (59.5)
Final TIMI 0/1 93/5,780 (1.6)
Final TIMI 2 303/5,780 (5.2)
Final TIMI 3 5,384/5,780 (93.1)
Post-PCI complications
Final no reﬂow 8/5,782 (0.1)
Final perforation 3/5,782 (0.1)
Final dissection 13/3,308 (0.4)
Final abrupt closure 7/5,783 (0.1)
Values are n/N (%), mean  SD, or median (interquartile range).
GPI ¼ glycoprotein IIb/IIIa inhibitor; MI ¼ myocardial infarction; MLD ¼ mini
reference vessel diameter; TIMI ¼ Thrombolysis In Myocardial Infarction; TLR ¼more extensive target lesion calciﬁcation were more likely to be
older, have renal insufﬁciency, lower left ventricular ejection
fraction, and higher white blood cell count at baseline and
more frequently had undergone prior PCI. Target lesion
calciﬁcation was more frequent among the STEMI populationral Outcomes Stratiﬁed by the Severity
Moderate
Calciﬁcation
(N ¼ 1,788)
Severe
Calciﬁcation
(N ¼ 402) p Value
735/1,788 (41.1) 173/402 (43.0) 0.73
284/1,788 (15.9) 51/402 (12.7) <0.0001
769/1,788 (43.0) 178/402 (44.3) 0.02
1.40  0.75 1.38  0.86 <0.0001
1.50  0.89 1.53  0.96 <0.0001
1,376/1,764 (78.0) 303/380 (79.7) 0.44
14.4 (10.1–21.0) 14.9 (10.0–20.0) <0.0001
2.80 (2.45–3.19) 2.84 (2.43–3.19) 0.08
0.52 (0.00–0.89) 0.44 (0.00–0.84) 0.0003
81.0 (66.6–100.0) 84.3 (67.2–100.0) 0.0004
720/2,428 (29.7) 211/550 (38.4) <0.0001
52/2,422 (2.1) 18/549 (3.3) 0.06
1,073/2,422 (44.3) 299/549 (54.5) <0.0001
1,121/2,430 (46.1) 264/550 (48.0) <0.0001
980/2424 (40.4) 259/549 (47.2) <0.0001
527/2424 (21.7) 92/549 (16.8) <0.0001
907/2424 (37.4) 189/549 (34.4) 0.42
660/1787 (36.9) 136/401 (33.9) 0.04
677/1787 (37.9) 164/401 (40.9) <0.0001
43.0 (25.9–63.3) 46.7 (30.1–70.5) <0.0001
2.71 (2.39–3.05) 2.69 (2.38–3.01) 0.31
2.32 (1.96–2.68) 2.26 (1.87–2.65) 0.02
7.0 (3.3–11.4) 7.14 (2.7–12.3) 0.26
17.7 (11.3–24.6) 18.5 (12.7–30.0) <0.0001
2.17 (1.72–2.65) 2.18 (1.72–2.68) 0.04
869/2,421 (35.9) 255/548 (46.5) <0.0001
325/2,421 (13.4) 69/548 (12.6) 0.008
1,227/2,421 (50.7) 224/548 (40.9) <0.0001
52/2,407 (2.2) 26/548 (4.7) <0.0001
149/2,407 (6.2) 51/548 (9.3) 0.0003
2,206/2,407 (91.6) 471/548 (85.9) <0.0001
7/2,411 (0.3) 5/547 (0.9) 0.001
3/2,408 (0.1) 0/547 (0.0) 0.43
8/1,203 (0.7) 4/213 (1.9) 0.01
9/2,411 (0.4) 6/547 (1.1) <0.0001
mum lumen diameter; PCI ¼ percutaneous coronary intervention; RVD ¼
target lesion revascularization.
Table 4 1-Year Rates of Major Events Stratiﬁed by the Severity of Target Lesion Calciﬁcation
No/Mild
Calciﬁcation
(N ¼ 4,665)
Moderate
Calciﬁcation
(N ¼ 1,788)
Severe
Calciﬁcation
(N ¼ 402) p Value
Moderate/Severe
Calciﬁcation
(N ¼ 2,190) p Value*
Death 128 (2.8) 73 (4.2) 25 (6.3) 0.0001 98 (4.6) 0.0002
Cardiac 83 (1.8) 50 (2.8) 16 (4.0) 0.002 66 (3.1) 0.001
Noncardiac 39 (0.9) 21 (1.3) 8 (2.1) 0.06 29 (1.4) 0.06
MI 326 (7.3) 133 (7.6) 37 (9.4) 0.22 170 (8.0) 0.23
Q-wave 72 (1.6) 49 (2.8) 6 (1.5) 0.005 55 (2.6) 0.005
Non–Q-wave 257 (5.7) 87 (5.0) 31 (7.9) 0.08 118 (5.5) 0.87
Death or MI 430 (9.5) 189 (10.7) 56 (14.1) 0.005 245 (11.3) 0.01
Ischemic TLR 261 (6.0) 140 (8.2) 22 (8.7) 0.002 162 (8.2) 0.002
Ischemic TVR 331 (7.5) 157 (9.2) 31 (11.0) 0.05 188 (9.4) 0.02
MACE 582 (12.9) 269 (15.3) 67 (19.9) 0.003 336 (16.1) 0.001
Stent thrombosis
Deﬁnite 78 (1.7) 50 (2.9) 7 (1.9) 0.01 57 (2.7) 0.008
Probable 29 (0.7) 8 (0.5) 2 (0.5) 0.72 10 (0.5) 0.43
Deﬁnite/probable 107 (2.5) 58 (3.4) 9 (2.4) 0.08 67 (3.2) 0.047
Values are Kaplan-Meier estimates presented as n (%). *No/mild versus moderate/severe.
MACE ¼ major adverse cardiac events; TVR ¼ target vessel revascularization; other abbreviations as in Table 3.
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advanced age, male sex, history of hypertension, and STEMI
presentation were independent predictors of moderate/severe
target lesion calciﬁcation (Table 2).
Compared with those without calciﬁcation, moderately
and severely calciﬁed lesions were longer, were more often
total occlusions and bifurcations, and were more likely to
contain thrombi (Table 3, Online Table 2). Patients with
moderate and severe target lesion calciﬁcation also had more
extensive coronary disease, requiring a greater number of
stents implanted. A similar proportion of DES were used
in all groups. Patients with greater target lesion calciﬁcation
were more likely to have suboptimal angiographic results
after PCI, with higher residual stenosis, more slow ﬂow, no
reﬂow, dissection, and abrupt closure.
Clinical outcomes. As shown in Table 4 and Figures 1 and
2, PCI in patients with moderately and severely calciﬁedFigure 1
Adverse Outcomes Through 1 Year According
to Severity of Target Lesion Calciﬁcation
Comparison of the cumulative event rates through 1 year in patients stratiﬁed by
no to mildly, moderately, and severely calciﬁed target lesions. Rates of death,
cardiac death, deﬁnite stent thrombosis (ST), ischemia-driven target revasculari-
zation, and major adverse cardiovascular events (MACE) all demonstrated signif-
icant overall trends between the calciﬁcation groups. MI ¼ myocardial infarction;
TLR ¼ target lesion revascularization.lesions was associated with higher unadjusted 1-year rates of
death, death/MI, ischemia-driven TLR and target vessel
revascularization, stent thrombosis, and MACE. Among pa-
tients with calciﬁed target lesions, event rates tended to be
greater in patients with heavy compared with moderate
calciﬁcation. Among patients who received >1 stent and
developed deﬁnite/probable stent thrombosis within 1 year,
there were 4 of 9 (44.4%) in the severe calciﬁcation group, 33
of 58 (56.9%) in the moderate calciﬁcation group (37 of 67
[55.2%] in the combined moderate/severe calciﬁcation group),
and 46 of 107 (43%) in the none/mild calciﬁcation group (p¼
0.11). By multivariable analysis, PCI of moderate/severe target
lesion calciﬁcation was independently associated with 1-year
rates of deﬁnite stent thrombosis (hazard ratio [HR]: 1.62;
95% conﬁdence interval: 1.14 to 2.30; p ¼ 0.007) and
ischemic TLR (HR: 1.44; 95% conﬁdence interval: 1.17 to
1.78; p ¼ 0.0007) but not with death or MI (Table 5).
Discussion
The current report, drawn from a cohort of 6,855 patients
undergoing PCI for ACS (NSTEACS and STEMI) is by far
the largest study to date to speciﬁcally evaluate the incidence,
predictors, and impact of target lesion calciﬁcation on prog-
nosis after stent implantation in this high-risk patient pop-
ulation. The main results of the present study were as follows:
1) target lesions in NSTEACS and STEMI were frequently
calciﬁed, as assessed by an angiographic core laboratory;
2) PCI in patients with moderately and severely calciﬁed
target lesions compared with those with no or mild calciﬁ-
cation was associated with suboptimal angiographic results
and procedural complications; and 3) PCI of calciﬁed lesions
was independently predictive of adverse ischemic outcomes,
including deﬁnite stent thrombosis and unplanned ischemia-
driven repeat revascularization within 1 year post-PCI, as
compared with patients in whom all target lesions had no or
only mild calciﬁcation.
Figure 2 Time-to-Event Curves Through 1 Year According to the Severity of Target Lesion Calciﬁcation
Comparison of the cumulative event rates through 1 year in patients stratiﬁed by no to mildly (none/mild) compared with moderately to severely (moderate/severe) calciﬁed
target lesions. (A) All-cause death. (B) Cardiac death. (C) Deﬁnite stent thrombosis. (D) Ischemia-driven target lesion revascularization. HR ¼ hazard ratio; other abbreviation
as in Figure 1.
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1850Lesions responsible for ACS are typically considered to
be soft, lipid rich, friable, and not calciﬁed (19). Contrary to
these expectations, by commonly accepted core laboratory
angiographic criteria, moderately or severely calciﬁed coro-
nary lesions were surprisingly frequent in the present study.
Indeed, approximately 27% of patients with NSTEACS and
38% of patients with STEMI had one or more moderately/
severely calciﬁed target lesions requiring PCI. Most
prior randomized DES trials (1–5,20–26) excluded patients
with operator-assessed moderate or severe target lesion
calciﬁcation. Nonetheless, 29.4% of the treated lesions in
the ACUITY and HORIZONS-AMI trials were moder-
ately or severely calciﬁed as assessed by an independent
angiographic core laboratory, evidence that interventional
cardiologists underestimate the severity of calciﬁcation.
Other contemporary DES studies in which a “real-world”
population was enrolled have also reported high rates of
target lesion calciﬁcation. In the COMPARE (Comparison
of the Everolimus-Eluting XIENCE-V Stent With thePaclitaxel-Eluting TAXUS LIBERTÉ Stent in All-Comers)
trial, in which 59.7% of 1,800 enrolled patients had ACS,
33.3% of lesions were reported to be calciﬁed (27).
Previous small to moderately sized studies, mostly from
the BMS era, reported higher rates of peri-procedural
complications and/or restenosis after PCI of calciﬁed
lesions (10–12,28). Surprisingly few reports, however, have
commented on the safety and efﬁcacy of DES treatment of
calciﬁed lesions. In the largest prior study of 1,537 patients
undergoing PCI of moderately/severely calciﬁed lesions
(653 of whom received DES by operator preference), DES
use was associated with lower rates of adverse ischemic
outcomes than BMS (12). No prior study has examined the
impact of target lesion calciﬁcation speciﬁcally in a high-risk
ACS population, in whom 1-year rates of cardiac death and
stent thrombosis are increased. The present large-scale study
of 6,855 patients with ACS undergoing PCI, approximately
80% of whom were treated with DES, demonstrated
that treatment of calciﬁed target lesions remains a strong
Table 5 Independent Predictors of 1-Year Clinical Outcomes
Hazard Ratio (95% CI) p Value
All-cause death
Moderate/severe target lesion
calciﬁcation
1.10 (0.81–1.48) 0.55
Age (per 10-yr increase) 1.73 (1.47– 2.02) <0.0001
Diabetes 2.10 (1.56–2.83) <0.0001
Baseline renal insufﬁciency 1.85 (1.30–2.64) 0.0007
Thrombus 1.44 (1.07–1.93) 0.02
Cardiac death
Moderate/severe target lesion
calciﬁcation
1.03 (0.70–1.50) 0.89
Age (per 10-yr increase) 1.86 (1.59–2.17) <0.0001
Diabetes 2.06 (1.42–3.00) 0.0002
Baseline minimal luminal diameter 0.47 (0.29–0.77) 0.002
Randomized to bivalirudin 0.68 (0.47–0.98) 0.04
Extent of disease (per 1-mm increase) 1.01 (1.00–1.01) 0.05
MI
Moderate/severe target lesion
calciﬁcation
1.06 (0.86–1.30) 0.58
Baseline renal insufﬁciency 1.75 (1.41–2.17) <0.0001
Prior CABG surgery 1.61 (1.27–2.05) <0.0001
Lesion length 1.01 (1.01–1.02) 0.0002
Number of attempted vessels 1.39 (1.13–1.72) 0.002
Thrombus 0.75 (0.59–0.92) 0.006
Prior percutaneous coronary
intervention
1.33 (1.06–1.67) 0.01
Previous MI 1.30 (1.03–1.63) 0.03
Deﬁnite stent thrombosis
Moderate/severe target lesion
calciﬁcation
1.62 (1.14–2.30) 0.007
Age (per 10-yr increase) 0.85 (0.74–0.98) 0.003
Baseline minimal luminal diameter 0.62 (0.41–0.95) 0.03
Ischemia-driven TLR
Moderate/severe target lesion
calciﬁcation
1.44 (1.17–1.78) 0.0007
Prior PCI 1.80 (1.46–2.21) <0.0001
Diabetes (insulin treated) 1.80 (1.31–2.45) 0.0002
Age (per 10-yr increase) 0.87 (0.78–0.96) 0.002
Drug-eluting stent 0.78 (0.62–0.99) 0.04
Other covariates included in the models all-cause death: drug-eluting stent, male sex, hypertension,
previous MI, previous PCI, previous CABG, number of attempted vessels, any left anterior descending
artery (LAD) attempted, randomized to bivalirudin, extent of disease, lesion length, baseline RVD,
baseline MLD, and modiﬁed American College of Cardiology (MACC)/American Heart Association
>B2; cardiac death: drug-eluting stent, male sex, hypertension, previous MI, and number of
attempted vessels; myocardial infarction: drug-eluting stent, age, male sex, diabetes, hypertension,
any LAD attempted, randomized to bivalirudin, extent of disease, baseline RVD, baseline MLD, MACC
>B2, and left ventricular ejection fraction (LVEF) (core laboratory assessed); ischemia-driven TLR:
male sex, diabetes, current cigarette smoker, hypertension, previous MI, previous CABG, number of
attempted vessels, any LAD attempted, baseline creatinine clearance <60 ml/min, baseline WBC
count, randomized to bivalirudin, randomized to heparin, LVEF (core laboratory assessed), extent of
disease, ostial lesion, lesion length, presence of thrombus, TIMI 0/1, baseline RVD, baseline degree
stenosis, baselineMLD,MACC>B2, biomarker positive, and ﬁnal no reﬂow; deﬁnite stent thrombosis:
drug-eluting stent, male sex, diabetes, hypertension, previous MI, number of attempted vessels,
randomized to bivalirudin, and extent of disease.
Abbreviations as in Tables 2 and 3.
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1851predictor for adverse safety and efﬁcacy outcomes in the
contemporary PCI era. After adjustment for imbalances in
measured confounders, treatment of calciﬁed target lesions
compared with no calciﬁcation was independently associated
with a 62% increase in stent thrombosis and a 44% increase
in ischemic TLR within 1 year of the procedure.Several mechanisms may explain the poor outcomes after
PCI of calciﬁed lesions. First, it is well known that stent
underexpansion is frequent in heavily calciﬁed lesions and
may increase the risk for restenosis and stent thrombosis
(29–31). As shown in the current report, the presence of
calciﬁcations was associated with an increase in the rate of
ischemic events at 1 year, especially inside the ﬁrst 30 days
(Fig. 1, Online Fig. 1), reﬂecting the detrimental impact
of calciﬁcations during stent implantation and resulting in
an increase in acute and subacute stent failure. Second,
difﬁculty in delivering stents may lead to structural device
damage and, in the case of DES, may result in tearing or
stripping the polymer, creating a prothrombotic/inﬂam-
matory nidus and/or promoting neointimal proliferation
(7). Third, a relationship between the severity of cal-
ciﬁcation and blood thrombogenicity has been reported.
Borissoff et al. (32) demonstrated a positive independent
association between greater in vivo thrombin generation and
the presence and severity of coronary calciﬁcation. Similarly,
Chirumamilla et al. (33) showed that patients treated with
aspirin and clopidogrel in whom severe coronary calciﬁca-
tion was versus was not visualized by intravascular ultra-
sound (IVUS) had higher platelet reactivity after PCI.
Finally, several genetic loci have recently been associated
with the development of vascular calciﬁcation and clinical
events such as myocardial infarction (34,35). In the present
study, PCI of calciﬁed lesions was associated with subop-
timal post-PCI results, including the more frequent oc-
currence of serious angiographic complications such as no
reﬂow, dissection, and abrupt closure and lower ﬁnal rates
of Thrombolysis in Myocardial Infarction ﬂow grade 3. PCI
of calciﬁed lesions in the setting of high platelet reactivity
(as is typically present in ACS [36]) may represent the
perfect storm for both procedural complications as well as
early and late stent thrombosis. Inclusive of the above, the
presence of coronary calciﬁcation may represent a marker of
poorer outcome and may not be the entire cause of worse
outcome at follow-up. Although target lesion calciﬁcation
was identiﬁed as an independent predictor of stent
thrombosis and TLR, it is possible that even if technical
advances were to obviate the negative consequences of
calciﬁcation itself, the outcomes of these patients may still
be worse.
Advanced age, male sex, hypertension, and STEMI pre-
sentation were independently associated with the presence of
calciﬁed target lesions in the current study. In prior studies
of patients with stable coronary artery disease, in addition to
older age, the extent of atherosclerosis and prior CABG
were identiﬁed as independent predictors of calciﬁcation
(37,38). This discrepancy may in part be explained by the
different nature of the study populations (ACS vs. stable
coronary disease). In addition, patients with chronic kidney
disease (whether or not requiring dialysis) frequently have
extensive coronary calciﬁcation, in part due to secondary
hyperparathyroidism (39). This population was underrep-
resented in our study population.
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1852Whether lesion decalciﬁcation prior to stent implantation
can improve event-free survival of patients with calciﬁed
lesions is an area of ongoing investigation. Despite initial
enthusiasm (40–44), the use of rotational atherectomy prior
to paclitaxel-eluting stent implantation in severely calciﬁed
lesions did not improve 9-month clinical or angiographic
outcomes in the ROTAXUS (Rotational Atherectomy Prior
to Taxus Stent Treatment for Complex Native Coronary
Artery Disease) randomized trial (45). Although rotational
atherectomy facilitated stent delivery and allowed a higher
rate of immediate procedural success in this study, in-
stent late loss at 9 months was greater after rotational
atherectomy compared with lesion preparation with con-
ventional balloon angioplasty alone prior to stenting (0.44 
0.58 mm vs. 0.31  0.52 mm; p ¼ 0.04). These data are
consistent with the results from studies in the balloon an-
gioplasty and BMS eras, which reported higher rates of
restenosis with rotational atherectomy (40,43,46–53).
Greater neointimal hyperplasia with rotational atherectomy
may be due to thermal injury, platelet activation, and medial
injury (54,55). Moreover, use of rotational atherectomy in
the setting of NSTEACS and STEMI in which thrombus is
almost always present (even if angiographically unapparent)
is considered an absolute contraindication. It is not therefore
surprising that only 48 patients (0.7%) underwent rotational
atherectomy in the present study. Ongoing and planned
studies will determine whether the prognosis after PCI of
calciﬁed lesions can be improved by use of novel, less trau-
matic devices for plaque debulking (56), perhaps coupled
with current-generation metallic DES or bioresorbable
vascular scaffolds, both of which are more potent than
paclitaxel-eluting stents at reducing restenosis.
Study limitations. The fact that an experienced indepen-
dent angiographic core laboratory analyzed all 6,855 an-
giograms in the present report is a major strength, removing
the element of operator variability and bias inherent in all
prior studies. The large sample size of the present analysis
also affords robust identiﬁcation of predictors of target lesion
calciﬁcation and adverse events. Independent adjudication
of clinical events blinded to the angiographic ﬁndings is
also notable. However, as an observational post-hoc analysis,
the present analysis can only identify correlations, not
prove causality. Despite adjustment for measured covari-
ates, residual confounding may be present. The results of
the present study should therefore be considered hypothe-
sis generating. Even though the degree of calciﬁcation
was assessed by experienced angiographic core laboratory
technicians, the severity of calciﬁcation is underestimated
by angiography compared with IVUS (57,58). The present
study was underpowered to determine whether PCI of
severely calciﬁed as compared with moderately calciﬁed
target lesions was an independent predictor of adverse out-
comes, as suggested in unadjusted analyses. Moreover, by
arbitrary convention, only heavy calciﬁcation contributes
to the SYNTAX score (59), a deﬁnition equivalent to that
of severe calciﬁcation by QCA (18). The present reportsuggests that in addition to heavy or severe calciﬁcation,
moderate calciﬁcation, as assessed by an experienced an-
giographic core laboratory, also has signiﬁcant impact on
ischemic outcomes and therefore might be included in future
risk models. Prospective validation of this concept is
required. The studies pooled in the current report included
implantation of approximately 20% of BMS and 80% ﬁrst-
generation DES. Given recent reports showing superior
outcomes with second-generation DES (60), our ﬁndings
may have been different had more contemporary stents been
used. However, whether second-generation DES perform
better in severely calciﬁed lesions has yet to be demonstrated.
IVUS was not required in the present study, and whether its
use would improve risk stratiﬁcation or treatment outcomes
in calciﬁed ACS lesions is unknown. Finally, the current
report was limited to a 1-year follow-up after stent im-
plantation. Longer-term patient assessment is required to
determine if the adverse outcomes after PCI of calciﬁed
target lesions continue to accrue over time.
Conclusions
Target lesions in patients with NSTEACS and STEMI are
frequently moderately or severely calciﬁed, and PCI of such
lesions was independently predictive of stent thrombosis and
unplanned ischemia-driven TLR at 1 year, as compared with
treatment of lesions with absent or only mild calciﬁcation.
Novel approaches are urgently needed to improve outcomes
of high-risk patients with ACS with calciﬁed lesions
undergoing PCI.
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